Rotterdam, 18 October 2019 - Centrient Pharmaceuticals (“Centrient”), the global leader in the production and commercialisation of sustainable, enzymatic antibiotics, next generation statins and anti-fungals, announced that it has filed a second lawsuit against Dalas Biotech Limited (“Dalas”) for patent infringement.

Centrient Pharmaceuticals announced that on October 14th 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a second lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for patent infringement of Indian Patent Number 318914. This patent, which is owned by Centrient, claims an innovative enzyme for use in a process for manufacturing the amoxicillin trihydrate active pharmaceutical ingredient. By its complaint, Centrient seeks compensation for damages and a permanent injunction to prevent the infringing manufacture, use, sale in India and exportation out of India of Dalas’ active pharmaceutical ingredient containing amoxicillin trihydrate produced by an enzyme that amounts to infringement of Indian Patent No. 318914.

Karl Rotthier, CEO at Centrient said: “After having previously filed patent litigation against Dalas Biotech for patent infringement in India related to a process for the enzymatic manufacture of amoxicillin trihydrate, Centrient now furthers it enforcement actions by filing this second infringement action related to the innovative enzyme used in that process. Centrient will continue to rigorously enforce its IP assets worldwide against any additional potential infringers in India or abroad.”